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Dendritic cell (DC) trafficking from peripheral tissues to lymph nodes (LNs) is a key step 
required to initiate T cell responses against pathogens as well as tumors. In this context, 
cellular membrane protrusions and the actin cytoskeleton are essential to guide DC 
migration towards chemotactic signals. Caveolin-1 (CAV1) is a scaffolding protein that 
modulates signaling pathways leading to remodeling of the actin cytoskeleton and 
enhanced migration of cancer cells. However, whether CAV1 is relevant for DC function 
and specifically for DC migration to LNs is unknown. Here, we show that CAV1 expres-
sion is upregulated in DCs upon LPS- and TNF-α-induced maturation. CAV1 deficiency 
did not affect differentiation, maturation, or the ability of DCs to activate CD8+ T cells 
in  vitro. However, CAV1-deficient (CAV1−/−) DCs displayed reduced in  vivo trafficking 
to draining LNs in control and inflammatory conditions. In vitro, CAV1−/− DCs showed 
reduced directional migration in CCL21 gradients in transwell assays without affecting 
migration velocity in confined microchannels or three-dimensional collagen matrices. 
In addition, CAV1−/− DCs displayed reduced activation of the small GTPase Rac1, 
a regulator of actin cytoskeletal remodeling, and lower numbers of F-actin-forming 
protrusions. Furthermore, mice adoptively transferred with peptide-pulsed CAV1−/− DCs 
showed reduced CD8+ T cell responses and antitumor protection. Our results suggest 
that CAV1 promotes the activation of Rac1 and the formation of membrane protrusions 
that favor DC chemotactic trafficking toward LNs where they can initiate cytotoxic T cell 
responses.
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inTrODUcTiOn
Dendritic cells (DCs) are professional antigen-presenting cells 
specialized in initiating adaptive T cell responses. DCs circulate 
and patrol peripheral tissues, taking up protein antigens and 
processing them into small peptides that are presented at the cell 
surface by major histocompatibility complex (MHC) molecules. 
After recognition of pathogen- or danger-associated signals, 
DCs maturate and migrate via lymphatic vessels to secondary 
lymphoid organs [i.e., lymph nodes (LNs)] where they activate 
antigen-specific naïve T cells (1). DC maturation induces upregu-
lation of several proteins, including co-stimulatory molecules 
and cytokines (2) and also increases DC trafficking toward sec-
ondary lymphoid organs by increasing polarized migration and 
upregulating chemokine receptors, such as CCR7 (3, 4). Increased 
CCR7 expression allows DCs to detect increasing concentra-
tions of CCL19/CCL21 (5, 6), which promotes haptotactic DC 
migration to the lymph vessels and entering into T cell rich areas 
of LNs (paracortex) (7, 8). Trafficking of DCs from peripheral 
tissues to LNs involves several sequential steps: (1) mobilization, 
(2) detachment, (3) interstitial migration, (4) entry into the affer-
ent lymphatics, and (5) transit via the lymph (9).
To migrate through epithelial barriers, DCs extend F-actin 
membrane protrusions at the cell front to associate via integrins 
with extracellular substrates. These points of contact are cou-
pled to the cytoskeleton to transduce the internal force that is 
generated when myosin II contracts the actin network, allowing 
retrograde traction forces on the integrins to move the cell. 
Then to migrate through three-dimensional matrices, DCs use 
adhesion-independent amoeboid migration, which is driven by 
protrusive flowing of the actin network at the leading edge of 
the cell. Myosin II-dependent contraction of the trailing edge is 
required when DCs need to pass through narrow gaps. On their 
way to LNs, DCs also need to transmigrate into lymph vessels 
(3) and proteins expressed in the lymph vessels promote acto-
myosin-mediated cellular contraction in DCs (10, 11), thereby 
enhancing cell migration across the lymphatic endothelium 
(12). Once DCs reach the lumen of lymph vessels, chemokine 
signals like CCL21 gradients (13) and mechanical forces like 
hydrostatic pressure or friction (14) guide the “squeezing and 
flowing” of the actin cytoskeleton that defines amoeboid DC 
migration (13). Finally, DCs enter the LN and transmigrate to 
the paracortex (T cell rich area) (15), where they activate T cells. 
As indicated above, regulation of actin cytoskeleton remodeling 
is important in every step of DC trafficking (14). Indeed, it has 
been suggested that actin flow may determine cell speed and 
persistency (16), highlighting the importance of actin cytoskel-
eton dynamics during DC trafficking. Such fine-tuned control 
is achieved mostly by the small GTPases Rho (17), Cdc42 (18), 
and Rac1 (19). However, despite recent progress in this field, our 
understanding of these events in DCs is limited, and additional 
pathways or molecules that promote DC trafficking remain to 
be defined.
Caveolin-1 (CAV1) is a membrane-bound scaffolding protein 
implicated in caveolae formation (20) that interacts with and 
controls the activity of a large number of proteins involved in 
signaling pathways relevant to growth, survival and proliferation 
in different cell types (21–24). Accumulating evidence sup-
ports a role for CAV1 in cell migration. Indeed, it was shown 
that directional persistency and chemotaxis are reduced in 
CAV1-deficient fibroblasts (25). In cancer cells, CAV1 expres-
sion promotes cell migration and invasion in  vitro (26, 27) 
and metastasis in  vivo (28, 29). The molecular mechanisms 
that operate downstream of CAV1 in these models, involve an 
increase in Rac1 activity via activation of the recently identified 
CAV1/p85α/Rab5/Tiam1/Rac1 signaling axis (27). It was largely 
assumed that caveolin proteins were not expressed in leukocytes. 
However, emerging evidence indicates that they can be found in 
myeloid and, in some particular cases, lymphoid cells (30, 31). 
A few reports have shown CAV1 expression in DCs, but its role 
remains unclear. Some reports suggest that CAV1 is involved in 
caveolae-dependent endocytosis (32, 33). Another study suggests 
that CAV1 recruits and suppresses iNOS, thereby decreasing NO 
production and suppressing DC function during HSV-1 infection 
(34). Also, CAV1 has been shown to promote HIV-1 capture and 
lysosomal degradation by Langerhans cells (LCs), restricting viral 
integration and subsequent spreading (35). Interestingly, stimula-
tion of human LCs with TNF-α increased CAV1 transcript levels 
(36), suggesting that CAV1 expression may be upregulated upon 
maturation. Taken together, these observations suggest that 
CAV1 might be relevant for DC function by modulating their 
migratory capacity.
In this study, we describe for the first time that CAV1 expres-
sion is upregulated upon DC maturation. Using CAV1-deficient 
(CAV1−/−) mice, we show that CAV1−/− DCs displayed reduced 
in vivo trafficking to draining LNs in steady state and inflamma-
tory conditions. CAV1−/− DCs showed reduced migration toward 
CCL21 gradients in transwell assays, decreased Rac1 activity and 
lower numbers of F-actin-forming protrusions. Furthermore, 
peptide-pulsed CAV1−/− DCs elicited reduced CD8+ T  cell 
responses in vivo and poorer antitumor protection. Overall, our 
results suggest that CAV1 promotes migration of DCs to LNs, 
likely through Rac1-dependent actin cytoskeleton remodeling, to 
elicit effective T cell responses.
resUlTs
caV1 expression is Upregulated  
upon Dc Maturation
To determine what happens to CAV1 expression upon matura-
tion, we first evaluated by Western blot analysis CAV1 expres-
sion in purified spleen DCs (Sp-DCs) and bone marrow-derived 
DCs (BM-DCs) following stimulation with LPS and TNF-α 
(Figure  1; Figures S1A,B in Supplementary Material). CAV1 
expression was increased in Sp-DCs after 6 h of LPS stimulation 
(Figures 1A; Figure S1A in Supplementary Material). Both LPS 
and TNF-α induced a time-dependent increase in CAV1 expres-
sion following 6–24 h of stimulation in BM-DCs (Figures 1B,C; 
Figure S1B in Supplementary Material). Since TNF-α secretion 
is induced by LPS (Figure S1C in Supplementary Material), we 
next evaluated whether autocrine TNF-α was involved in LPS-
induced CAV1 upregulation. To this end, TNF-α was blocked 
using a neutralizing antibody present for 6- or 24  h during 
FigUre 1 | Caveolin-1 (CAV1) is expressed in dendritic cells (DCs) and upregulated upon maturation. CAV1 expression in DCs was assessed by Western blotting. 
GAPDH and actin were used as loading controls. CAV1 protein expression was quantified by densitometry analysis and standardized to loading control. Values 
normalized to untreated controls (NT) are shown. (a) Spleen DCs purified from wild-type mice were treated with LPS (100 ng/ml) for 6 h. (B,c) Bone marrow-derived 
DCs (BM-DCs) were stimulated with LPS (100 ng/ml) or TNF-α (20 ng/ml) for 0, 1, 3, 6, 12, or 24 h. (D) BM-DCs were treated with LPS (100 ng/ml) alone or in 
combination with a TNF-α blocking antibody (5 µg/ml) for 24 h. Values are presented as the mean ± SEM. *p < 0.05; n = 3 independent experiments.
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LPS stimulation. As shown in Figure  1D, the TNF-α block-
ing antibody reduced by over 50% CAV1 upregulation after 
24  h stimulation. However, blocking TNF-α did not change 
LPS-induced upregulation of CAV1 at an earlier time point 
(6  h) following LPS treatment (Figure S1D in Supplementary 
Material), indicating that LPS-induced upregulation of CAV1 
initially does not require TNF-α, but that secreted TNF-α then 
plays a predominant role at later time points.
To assess the role of CAV1 in DC function, we used a CAV1 
null (CAV1−/−) mouse model (37). To validate the model, we 
first determined the frequency of DCs present in spleen, LNs 
and skin (as an example of peripheral tissue). We found that DC 
frequency was the same in both CAV1−/− and wild-type (WT) 
mice for all the tested tissues (Figures S2A–C in Supplementary 
Material). Moreover, no differences were observed in terms of 
viability, differentiation, expression of lineage markers, and 
co-stimulatory molecules, as well as cytokine secretion when 
comparing BM-DCs generated from CAV1−/− with DCs from 
WT mice (Figure S2D in Supplementary Material). We also 
evaluated co-stimulatory molecule expression and neither 
CD14, CD40, CD86, CD38, PD-L1 nor MHC-I expression 
changed when comparing WT and CAV1−/− DCs, irrespective 
of their maturation status. The only difference detected was a 
minor reduction in CD80 and CCR7 expression in immature 
CAV1−/− DCs when compared with WT DCs. This difference was 
not evident when analyzing mature DCs though. Furthermore, 
cytokine secretion (IL-6, IL-12, and TNF-α) was the same for 
control or LPS-maturated WT or CAV1−/− DCs. Given that a 
key feature of DCs is to activate T cells, we evaluated whether 
CAV1 participates in DC-mediated CD8+ T  cell activation. 
In agreement with our previous data, both WT and CAV1−/− DCs 
pulsed with different concentrations of the OVA257–264 peptide 
(SIINFEKL) were equally efficient at inducing the proliferation 
of CFSE-stained OVA257–264-specific OT-I CD8+ T cells (Figure 
S3A in Supplementary Material). These results suggest that 
CAV1 deficiency in DCs does not affect either differentiation, 
maturation or the ability to activate CD8+ T cells in vitro.
caV1 Promotes Dc Trafficking to lns
To identify a possible role for CAV1 in DC function in  vivo, 
we tested whether CAV1 was involved in the trafficking of DCs 
from the periphery to LNs by performing the FITC painting 
assay. To this end, mice were inoculated with a FITC-containing 
solution at two different sites (left and right) of the lower 
back (38). To further induce inflammation and enhance skin 
DC migration, one site was additionally treated with dibutyl 
phthalate (DBP), which is a well-known skin irritant that 
promotes DC migration (39). As summarized in the scheme 
(Figure  2A), the accumulation of FITC-positive migratory 
DCs (FITC+CD11c+MHC-IIhigh) in the inguinal LN was evalu-
ated by flow cytometry after 20 h. Viable cells were gated for 
co-expression of CD11c and MHC-II to identify DCs (gating 
strategy shown in Figure S2D in Supplementary Material). 
As shown, the absence of CAV1 drastically impaired DC traf-
ficking to the inguinal LNs in both control and inflammatory 
conditions (Figure 2B). Indeed, 1.6% of WT DCs reached LNs 
as compared with only 0.1% for CAV1−/− DCs, indicating that 
the lack of CAV1 in DCs impaired almost completely migration 
in the control condition (Figure 2B, left panels). DBP-induced 
migration of WT DCs increased up to 25% as compared with 
only 10% for CAV1−/− DCs (Figure  2B, right panels). These 
results suggest that CAV1 expression is fundamental for DC 
trafficking from skin to the draining LNs.
As DC prevalence was similar in the skin of WT and CAV1−/− 
mice (Figure S2C in Supplementary Material), impaired DC 
trafficking to the LNs in CAV1−/− mice could not be attributed 
to reduced numbers of skin DCs. However, because these 
experiments were performed in mice that lacked the expression 
of CAV1 in all cell types, the effects observed for DCs may be 
attributed to changes in the environment rather than the DCs 
themselves. Thus, we performed an experiment where CAV1 
deficiency was restricted just to DCs. WT and CAV1−/− BM-DCs 
were labeled with carboxyfluorescein succinimidyl (CFSE) or 
Cell Trace Violet (CTV), respectively, mixed at a 1:1 ratio and then 
injected into the footpad of recipient WT mice. After 24 h, both 
FigUre 2 | Caveolin-1 (CAV1) favors dendritic cell (DC) trafficking to lymph nodes (LNs) in vivo (a,B). Back skin of wild-type (WT) and CAV1−/− mice were treated 
with FITC (left flank) or FITC + dibutyl phthalate (DBP) (right flank), as summarized in (a). (B) After 24 h, the arrival of skin-derived FITC+ DCs to inguinal LNs was 
evaluated. Representative density plots (top panels) and quantification of FITC+ DCs (bottom panels) under basal or DBP-induced conditions are shown. Each dot 
represents one animal, and the bar is the mean (*p < 0.05, n = 7). (c,D) WT and CAV1−/− bone marrow-derived DCs (BM-DCs) were stained with CFSE and Cell 
Trace Violet (CTV), respectively. Then, WT recipient mice were subcutaneously injected in the right footpad with 5 × 105 cells (1:1 ratio, WT to CAV1−/−) or with PBS 
as a control (left footpad). The arrival of CFSE (WT) or CTV (CAV1−/−) BM-DCs to the draining (right) and contralateral (left) popliteal LNs was evaluated 24 h later.  
(c) Scheme of footpad injection and gating analysis to analyze transferred BM-DCs. (D) Representative dot plots of DCs in the draining popliteal LNs are shown. 
Gates showing injected WT and CAV1−/− DCs are displayed. The migration index of WT or CAV1−/− DCs was calculated as {[% CTV stained DC in popliteal lymph 
nodes (PLN)]/(% CTV stained DC in input)}/[(% CFSE WT DC in PLN)/(% CFSE WT DC in input)]. Data are presented as dot plots with connecting lines per paired 
samples. **p < 0.01, n = 16 mice, from three independent experiments.
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draining and contralateral (control) popliteal LNs were obtained 
and processed to analyze the presence of transferred WT (CFSE-
positive) and CAV1−/− (CTV-positive) DCs by flow cytometry, 
as depicted in the scheme (Figure 2C, gating strategy similar to 
Figure S2B in Supplementary Material). As shown (Figure 2D), 
the frequency of CAV1−/− DCs in the draining popliteal LNs 
was reduced by nearly 50% compared with WT DCs. Neither 
WT nor CAV1−/− DCs were detected in the contralateral LNs. 
Taken together, these findings indicate that CAV1 intrinsically 
modulates the migratory behavior of DCs by promoting their 
trafficking to LNs, which represents a fundamental step to initi-
ate adaptive immune responses.
caV1 Promotes Dc Transmigration
To shed light on the mechanisms by which CAV1 favors DC 
trafficking to LNs, we employed in vitro assays that represent the 
different types of migration that enable DCs to reach second-
ary lymphoid organs (14): confined unidirectional migration 
(microchannels), three-dimensional (collagen matrix), and 
two-dimensional migration (transwell). While microchannels 
mimic the confined spaces typically present in peripheral tissues 
(40), collagen matrix migration resembles amoeboid interstitial 
migration and transwell assays emulate entry to lymphatic 
vessels and transmigration across lymphatic endothelium. We 
first evaluated whether CAV1 modulates DC trafficking using 
fabricated microchannels, as well as in collagen matrix using 
CCL21 as a chemoattractant. Migration velocities in both assays 
were similar for WT and CAV1−/− DCs (Figures 3A,B), indicat-
ing that intrinsic DC motility is independent of CAV1. To enter 
lymphatic vessels, DCs must pass through narrow openings 
-loose flaps of about 2–3 µm in diameter—present at the begin-
ning of initial lymphatic capillaries (41), in a process that requires 
FigUre 3 | Caveolin-1 (CAV1) promotes dendritic cell (DC) transmigration, actin membrane protrusions, and Rac1 activation. Migration of wild-type (WT) or 
CAV1−/− bone marrow-derived DCs (BM-DCs) in different in vitro assays. (a) BM-DCs treated or not with LPS (1 µg/ml, for 30 min) were individually tracked in 
confined microchannels (4 µm). After 5–6 h, cell images at different positions along the channels were recorded during 10–12 h (one photo each 2 min) using an 
automated microscope. The reconstructed movie is analyzed, and the average speed of every cell obtained. In the box plots, the bars include 90% of the data 
points, the center corresponds to the median, and the box contains 75% of the data points. Data from two different experiments, n = WT: 221, WT + LPS: 153, 
CAV1−/−: 120, CAV1−/− + LPS: 236 cells (***p < 0.001). (B) Chemotactic migration of LPS-treated WT or CAV1−/− BM-DCs embedded in a 1% bovine collagen gel 
containing a CCL21 gradient. Mean velocity of LPS-DCs depicted as a function of the distance to the CCL21 source. In the box plots, the bars include 90% of the 
data points, the center corresponds to the median, and the box contains 75% of the data points. n = WT: 1,090, CAV1−/−: 1,169 tracks, from two independent 
experiments. (c) DC transwell migration. The bottom side of transwell membranes was coated with fibronectin to avoid losing migratory cell. In the bottom chamber, 
RPMI medium containing 0.5% fetal bovine serum with or without CCL21 (20 ng/ml) was added. Then, 2 × 105 of WT or CAV1−/− BM-DCs were seeded in the upper 
chamber, and migration was evaluated by counting cells on the bottom surface of the membrane. Left panel, immature BM-DC migration after 1 h. Right panel, 
LPS-matured BM-DC migration after 30 min. The migration index (relative to spontaneous WT DC migration) is shown. Bars are mean ± SEM (*p < 0.05, n = 3). (D) 
In the left panel, representative confocal microscopy images showing F-actin (phalloidin staining) in WT or CAV1−/− BM-DCs treated or not with LPS (100 ng/ml, 
24 h). To the right, the quantification of protrusions per cell is shown. Each dot corresponds to one cell, and the black bar represents the mean (*p < 0.05, 
**p < 0.01, and ***p < 0.001, n = 18 cells, two experiments). (e) GTP-Rac1 levels were determined in WT and CAV1−/− DCs using pull-down assay followed by 
Western blot. Representative blots showing the active GTP-bound fraction and total Rac1. The ratio between active and total Rac1 is shown in the plot 
(densitometry analysis). Data are the mean ± SD (*p < 0.05, n = 3).
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direct contact with endothelial cells and matrix (42). Then, DCs 
transmigrate across lymphatic endothelium to reach the LNs 
(43). Hence, to determine if CAV1 was involved in facilitating 
these processes, a transwell migration assay was performed. As 
shown (Figure 3C, left panel), basal DC transmigration induced 
by exposure to CCL21 was severely reduced in CAV1−/− DCs. 
Moreover, LPS-induced transmigration was also reduced in 
CAV1−/− DCs (Figure  3C, right panel). Taken together, these 
observations suggested that CAV1 promotes DC trafficking to 
LNs by increasing transmigration.
It has been suggested that during DC transmigration, the cells 
actively push open the junction to enter the lymphatic capil-
lary (44). As actin cytoskeleton protrusions could be involved 
in the junction opening and transmigration across lymphatic 
endothelium, we evaluated the role of CAV1 in the formation 
of membrane protrusions. As shown (Figure  3D, left panel), 
actin microfilament staining using phalloidin revealed a reduced 
number of actin-based membrane protrusions for immature 
CAV1−/− DCs as compared with WT cells. LPS increased signifi-
cantly membrane protrusions in WT DCs; however, in CAV1−/− 
DCs almost 40% fewer projections were detected, suggesting that 
CAV1 promotes remodeling of the actin cytoskeleton in DCs. 
Previous reports have implicated the small GTPase Rac1 in actin 
cytoskeleton remodeling and formation of membrane protru-
sions in DCs (45), indicating that Rac1 inhibition decreased DC 
arrival to LNs (19). Therefore, Rac1 activity was determined in 
WT and CAV1−/− DCs by a pull-down assay that uses a GST-
PAK1 fusion protein to immunoprecipitate GTP-bound active 
Rac1. Then, Rac1 levels present in the pull-down fraction (Rac1-
GTP), and total DC lysates were analyzed by Western blotting. 
As shown (Figure 3E), Rac1 activation was severely reduced in 
CAV1−/− compared with WT DCs, thereby implicating CAV1 
in Rac1 activation in DCs. Taken together, our results suggest 
that CAV1 promotes DC migration to the LNs by increasing DC 
transmigration, likely through Rac1-mediated actin cytoskeleton 
remodeling.
FigUre 4 | Caveolin-1 (CAV1) promotes the ability of dendritic cells (DCs) to induce antigen-specific CD8+ T cell responses. (a) Scheme of the experimental 
procedure. At day 0, 1 × 106 OVA257–265-pulsed wild-type (WT) or CAV1−/− bone marrow-derived DCs (BM-DCs) were transferred to recipient WT mice. After 7 days, 
blood samples were taken, and CD8+ T cell responses were analyzed. (B) Cells were stimulated with control (trp2180–188) or OVA257–265 peptides for 2 h, and then 
brefeldin A-containing solution (Golgi plug) was added for another 6 h (8 h total stimulation). Afterward, cells were stained and analyzed by flow cytometry. 
Representative dot plots of IFN-γ expression on gated CD3++CD8+ T cell population and the percentage of IFN-γ-producing CD8+ T cells are shown. Bars are  
the mean ± SEM (*p < 0.05, n = 7 mice, from two independent experiments). (c) Freshly isolated cells were stained with H-2 Kb/SIINFEKL (OVA257–265 peptide) 
dextramer to determine antigen-specific CD8+ T cells. Representative density plots and quantification of frequency of dextramer-positive from totalCD3+CD8+  
T cell population are shown. Data are the mean ± SEM (*p < 0.05, n = 5–6 mice from two independent experiments).
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caV1 enables Dcs to generate Tumor-
Protective cD8+ T cell responses
To assess the potential consequences of CAV1 in promoting 
DC trafficking to the LNs, we evaluated the ability of DCs to 
initiate antigen-specific CD8+ T  cell responses in  vivo (46). 
Therefore, WT recipient mice were transferred with WT and 
CAV1−/− DCs pulsed with OVA257–264 peptide to elicit CD8+ 
T  cell responses independently of antigen uptake, processing, 
and presentation. Seven days later, OVA257–264-specific CD8+ 
T cell responses were determined in peripheral blood by ex vivo 
peptide stimulation followed by intracellular IFN-γ staining 
and flow cytometry analysis (see scheme in Figure  4A). As 
shown (Figure  4B), higher frequencies of IFN-γ-producing 
CD8+ T cells in response to OVA257–264 ex vivo stimulation were 
detected for WT DC-immunized mice compared with the 
CAV1−/− DC-immunized group. To confirm that CAV1−/− DCs 
elicited reduced CD8+ T cell responses, and not CD8+ T cells 
with an impaired ability to produce IFN-γ, the total frequencies 
of OVA257–264-specific CD8+ T cells were determined by staining 
with a H-2Kb/OVA257–264 multimer, which labels OVA257–264-
specific CD8+ T cells regardless of the ability to respond to ex 
vivo peptide stimulation. As anticipated, reduced frequencies of 
H-2Kb/OVA257–264-specific CD8+ T cells were detected in mice 
immunized with CAV1−/− DCs as compared with WT DCs 
(Figure 4C). Given our results showing that WT and CAV1−/− 
DCs activate CD8+ T  cells equally well when they interact 
in vitro (Figure S3A in Supplementary Material), these results 
suggest that the impaired arrival of CAV1−/− DCs to lymphoid 
organs leads to reduced CD8+ T cell responses.
To validate these results in a functional model that relies on 
the cytotoxic activity of specific CD8+ T cells in vivo, we per-
formed tumor challenge experiments. To this end, recipient WT 
mice transferred with OVA257–264-loaded WT or CAV1−/− DCs 
were challenged with ovalbumin-expressing B16 (B16-OVA) 
melanoma cells, and tumor growth was monitored every 
2–3 days (Figure 5A). Significant suppression of tumor growth 
FigUre 5 | Caveolin-1 (CAV1) promotes dendritic cell (DC)-mediated 
antitumor protection. (a) Scheme showing experimental procedure. Initially, 
1 × 106 OVA257–265-pulsed wild-type (WT) or CAV1−/− BM-DCs were 
transferred to WT recipient mice. The control group was injected with PBS 
(vehicle). After 13 days, mice were challenged s.c. with 2 × 105 B16F10-OVA 
(B16-OVA) cells injected into the right flank. Tumor growth evaluation started 
5 days after challenge and was carried out until all the animals were dead. 
The animals were sacrificed when the length, width, or height surpassed 
15 mm. Groups were defined as: control mice group (gray triangles), 
OVA257–265-loaded WT (WT DCs, red squares), and OVA257–265-loaded 
CAV1−/− DCs (CAV1−/− DCs, blue circles). (B) Average tumor growth curves 
are shown (*p < 0.05, t-test, n = 8–10 mice). (c) Survival curves. The mean 
survival times were as follows: Ctrl group, 22 days; WT DC group, 28 days; 
CAV1−/− DC group, 22,5 days (*p < 0.05, n = 8–10 mice, three different 
experiments).
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(Figure 5B) and extended survival (Figure 5C) were observed in 
mice receiving WT DCs as compared with control-treated (Ctrl) 
mice. By contrast, tumor suppression and survival were severely 
compromised in mice that received CAV1−/− DCs. These results 
indicate that CAV1 promotes the ability of adoptively trans-
ferred DCs to initiate tumor-protective CD8+ T cell responses. 
Overall, our data identify a novel role for CAV1 in DC function 
by promoting DC trafficking to the LNs to efficiently initiate 
protective cytotoxic CD8+ T cell responses.
DiscUssiOn
In this study, we show that CAV1 expression is upregulated in 
DCs upon maturation and plays a pivotal role in promoting the 
trafficking of DCs to LNs, a crucial step to initiate protective 
adaptive T  cell responses. Furthermore, our data support the 
notion that CAV1 increases DC trafficking by enhancing trans-
migration, likely through Rac1-dependent remodeling of actin 
cytoskeleton. These findings unveil a novel function for CAV1 in 
DCs with a relevant effect in CTL-mediated responses.
Although it was largely assumed that CAV1 was not expressed 
in leukocytes, some studies indicated that it may be expressed in 
the myeloid compartment (30). Previous studies had described 
the presence of CAV1 in macrophages (47) and DCs (32–34) 
where the protein played contradictory roles in virus–host 
interaction. In DCs, CAV1 has been shown to prevent HIV virus 
infection (35), as well as to dampen host antiviral responses 
mediated by nitric oxide production (34). However, none of these 
studies evaluated changes in CAV1 expression upon maturation, 
its role in migration or initiation of adaptive immune responses. 
Here, we show that CAV1 is expressed in DCs at steady state, 
and progressively upregulated upon maturation induced by 
LPS or TNF-α. Moreover, LPS-induced CAV1 upregulation 
is reinforced at later time points in an autocrine manner by 
TNF-α (Figure 1; Figure S1 in Supplementary Material). Thus, 
it seems that TLR4 and TNFR signaling are relevant for CAV1 
expression. Given that NF-κB is a master regulator of TLR- and 
TNF-α-dependent DC maturation (48), as well as CAV1 expres-
sion in other cell types (49), our data suggest that NF-κB may 
participate in the control of CAV1 expression in DCs. First, LPS 
is known to induce NF-κB activation via TLR4 signaling (50), 
resulting in TNF-α production. Second, TNF-α activates the 
TNF receptor that can also lead to NF-κB activation (51, 52). 
Interestingly, TNF-α was described to increase CAV1 transcript 
levels in human LC (36), a well-known migratory DC subset 
(53). Taken together, the previously published results and our 
findings suggest that maturation is linked to CAV1 upregulation 
in DCs, probably via NF-κB. Therefore, CAV1 upregulation is 
likely to represent a rather common event in DC biology.
In addition to its well-established role in endocytosis, an emerg-
ing role in cell migration has been ascribed to CAV1. However, 
such a role in immune cells, and particularly in DCs, had not been 
described yet. Here, we demonstrate that CAV1 promotes migra-
tion to draining LNs using two complementary in vivo models. 
Both endogenous CAV1−/− DCs in knockout mice, as well as 
CAV1−/− DCs transferred into WT mice, displayed impaired traf-
ficking to LNs compared with their WT DC counterpart. These 
in  vivo assays show that, even under inflammatory conditions, 
a major proportion of DCs remain in the tissue and only a few 
of them are able to find their way through lymph vessels to the 
draining LNs, inefficiently reaching more distant tissues (6). 
Hence, our results argue that CAV1 promotes a rate-limiting step 
of DC migration to the LNs.
To define more precisely the underlying mechanism(s) by 
which CAV1 favored DC trafficking to LNs, different in  vitro 
migration assays were performed. Our results show that neither 
amoeboid DC migration nor migration in confined environ-
ments were dependent on CAV1 expression (Figures  3A,B). 
However, results from the transwell assay (Figure  3C), which 
relies on migration through two-dimensional surfaces and 
passing through small pores, suggest that CAV1 promotes DC 
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transmigration through afferent lymphatic vessels. First, DCs 
need to enter into lymphatic capillaries through preformed 
pores present in the basement membrane (41, 54), which are 
about 3 µm in diameter (55), but can be stretched to allow DC 
entry during transmigration (41, 44). Thus, in our experiments 
we used transwells with 8 µm size pores to maximize DC trans-
migration. After entering into the lumen of lymphatic capillar-
ies, DCs need to migrate through the lymphatic endothelium 
surface following CCL21 gradients toward LNs (42). Hence, our 
results suggest that CAV1−/− DCs are unable to appropriately 
enter and migrate through lymph vessels. Since these processes 
are dependent on cytoskeleton remodeling, impaired forma-
tion of actin-forming protrusions observed in CAV1−/− DCs 
may provide an explanation for our results showing reduced 
in vivo and in vitro migration. Given that Rac1 modulates actin 
protrusion formation and DC migration (19, 45, 56), and that 
Rac1 activity is reduced in CAV1−/− DCs, CAV1 may control DC 
migration by promoting Rac1 activity. It appears that formation 
of actin protrusions is a major consequence of Rac1 activity, 
which is linked to DC migration. As described by Benvenuti 
et  al., DC migration in  vivo was impaired in Rac1/2-deficient 
cells, as were rearrangements of actin cytoskeleton after block-
ing the Rac1 pathway (19). Moreover, CD81 promotes in vitro 
migration by increasing membrane protrusions via Rac1 activa-
tion (45). Also, CD37 ablation in DCs impairs cell migration 
in vitro (determined using a transwell assay), reduced dendrite 
formation in vivo and decreased Rac1 activity (56). Altogether, 
our results support the notion that CAV1 regulates DC migra-
tion by controlling actin cytoskeleton remodeling through 
activation of Rac1 and thus promotes efficient DC trafficking to 
LNs. However, further studies are required to precisely define 
the underlying mechanism(s).
The potential implications of CAV1 in promoting the ability 
of DCs to reach the LNs and initiate CD8+ T  cell responses 
can be extrapolated to therapeutic interventions. DC-based 
immunotherapy has been proposed to have the potential to 
induce immune responses against cancer cells, but clinical 
trials have met with modest success (57, 58). Despite their 
initial poor clinical benefit, antigen-pulsed DC vaccines were 
recently shown to increase the breadth and diversity of mela-
noma neoantigen-specific T cells (59), and overall survival rates 
(57, 60) in stage IV melanoma patients, renewing the interest 
in employing DCs in clinical treatments. Migration to the LNs 
appears to represent a key limiting factor that determines the 
success of DC-based vaccination and the ability to induce T cell 
immune responses, which lead to favorable clinical outcomes 
(61). Indeed, DC migration to LNs seems to be a generally 
inefficient process in DC-based treatments (62), and as a conse-
quence, the generation of specific adaptive immune responses 
is also suboptimal (63). Hence, the identification of molecular 
markers and the development of therapeutic strategies that 
improve DC trafficking need to be considered. Given our 
results showing that CAV1 promotes DC trafficking and thus 
the generation of more effective antitumor immune responses, 
CAV1 status may represent a novel marker for DC function 
and increasing CAV1 expression in DCs may help to improve 
DC-based immunotherapies.
In summary, our study demonstrates that CAV1 is upregu-
lated in DCs upon maturation and promotes DC migration to 
LNs, probably by increasing actin cytoskeleton remodeling via 
Rac1 activation. While CAV1 expression in DCs is dispensable 
for CD8+ T cell activation in vitro, it enables DCs to reach the 
LNs to elicit effective antitumor CD8+ T cell responses in vivo. 
Therefore, our data identify a novel, hitherto unappreciated 
function of CAV1 in DCs with important consequences for 
basic aspects of DC biology that may open up a novel therapeutic 
window of opportunity to improve DC-based vaccines.
MaTerials anD MeThODs
Mice
C57BL/6J CAV1 knockout mice (CAV1−/−, CAV1tm1Mls/J), 
C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I), and C57BL/6J WT 
mice, mice were purchased from Jackson Laboratories (Bar 
Harbor, ME, USA). Mice were maintained at the SPF animal 
facility of Fundación Ciencia & Vida, where breeding and experi-
mental procedures were carried out according to institutional 
guidelines. This study was carried out in accordance with the 
recommendations of the Comisión Nacional de Investigación 
Científica y Tecnológica, CONICYT.
Bone Marrow (BM)- and spleen-Derived 
Dcs
Bone marrow-derived DCs were generated from flushed BM 
suspension from freshly dissected femurs and tibias. Cells were 
centrifuged for 5 min at 400 × g, treated with Red Blood Cells 
lysis buffer (BioLegend, San Diego, CA, USA) for 5 min, washed 
with PBS, centrifuged again and then cultured for 6 days in sup-
plemented medium (RPMI medium; Hyclone, Logan, UT, USA) 
containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT, 
USA), 20 ng/ml granulocyte-macrophage colony stimulating fac-
tor (BioLegend, San Diego, CA, USA), 1% non-essential amino 
acids, 1% l-glutamine, 1% penicillin–streptomycin, and 0.1% 
β-mercaptoethanol (Invitrogen, Carlsbad, CA, USA). Sp-DCs 
were purified from freshly isolated spleen using the EasySep 
Mouse CD11c Positive Selection Kit (StemCell, Vancouver, 
BC, Canada) according to the manufacturer’s instructions and 
then cultured in supplemented RPMI medium. Freshly isolated 
Sp-DCs or BM-DCs at day 6 were treated with LPS 100 ng/mL 
(S. typhimurium, L6143 Sigma-Aldrich, St. Louis, MO, USA) or 
TNF-α (20 ng/ml, BioLegend, San Diego, CA, USA) for different 
times as specified in each figure. In some experiments, BM-DCs 
were treated with LPS (100  ng/ml) together with anti-TNF-α 
blocking antibody (1  µg/ml, BioLegend, San Diego, CA, USA, 
clone MP6-XT22).
Western Blotting
Dendritic cells (2  ×  106) were lysed in RIPA buffer (50  nM 
Tris–HCl, pH 7.4, 1% Triton-X, 0.5% Na-deoxycholate, 0.1% 
SDS, 150  mM NaCl, 2  mM EDTA, and 50  mM NaF) contain-
ing a protease inhibitor cocktail (cOmplete EDTA-free Protease 
Inhibitor Cocktail, Roche, Basel, Switzerland). Cell lysates were 
incubated for 15 min on ice and then centrifuged at 15,000 × g 
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for 10 min at 4°C to obtain the supernatant. Protein concentra-
tions were determined using the bicinchoninic acid protein 
assay kit (Thermo Scientific, Waltham, MA, USA) according 
to the manufacturer’s instructions. Samples’ concentration was 
normalized, and equal amount of samples were mixed with 6× 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) loading 
buffer [360 mM Tris–HCl (pH = 6,8), 60% glycerol, 12% SDS, 
10% 2-mercaptoethanol, 0.03% Bromophenol Blue] heated 
to 95°C for 5 min and stored at −20°C until used. Then, 40 µg 
protein per sample was separated by SDS-PAGE (12% gel) at 
120 V for 100 min in TGS buffer (25 mM Tris, 200 mM glycine, 
and 0.1% SDS) and then transferred to nitrocellulose membranes 
using a wet transfer Mini-Trans Blot system (Bio Rad, Hercules, 
CA, USA) at 400  mA for 90  min at 4°C in transference buffer 
(25 mM Tris, 200 mM glycine, 0.1% SDS, and 20% MeOH). The 
membranes were washed three times with PBS-Tween 0.05% 
and subsequently incubated with blocking solution (3% nonfat 
dry milk in PBS-Tween 0.05%) at room temperature for 1  h. 
Primary antibodies were incubated overnight at 4°C diluted 
in blocking solution: anti-CAV1 (1:4,000, BD Transduction 
Laboratories, Franklin Lakes, NJ, USA), anti-actin (1:5,000, 
Sigma-Aldrich, St. Louis, MO, USA), anti-GAPDH (1:5,000, 
Cell Signaling, Danvers, MA, USA), and anti-Rac1 (1:4,000, BD 
Transduction Laboratories, Franklin Lakes, NJ, USA). Then, the 
membranes were washed and incubated with anti-rabbit HRP-
linked secondary antibody (1:2,000, Sigma-Aldrich, St. Louis, 
MO, USA) for 1  h at room temperature in blocking solution. 
Chemiluminescence was detected using the Supersignal West 
Pico kit (Thermo Scientific, Waltham, MA, USA) followed by 
exposure to photographic films (CL-XPosure Films, Thermo 
Scientific, Waltham, MA, USA). The digitized images were used 
for densitometry analysis using ImageJ software (NIH, Bethesda, 
MD, USA). CAV1 levels were normalized by actin or GAPDH 
levels, depending on the experiment.
FiTc Painting assay
This procedure was performed as previously described (38). 
The back skin of mice was shaved and then inoculated on the 
right lateral flank with 12  µl of a 1% FITC solution (Isomer 
1, Sigma-Aldrich, St. Louis, MO, USA) prepared in acetone 
(control). The left flank was inoculated with 12 µl of a 1% FITC 
solution prepared in acetone plus DBP (1:1) to induce skin 
irritation. After 20–22  h, mice were sacrificed, and draining 
inguinal LNs were obtained, and single cell suspensions were 
prepared using a solution containing collagenase IV (5 mg/ml, 
Gibco, Thermo Scientific, Waltham, MA, USA) and DNAse I 
(5 mg/ml, AppliChem, Maryland Heights, MO, USA) in RPMI 
supplemented with 0.5% FBS for 45  min at 37°C in a shaker 
bath. Then, the cells were stained with either anti-CD11c PE/
Cy7-conjugated (clone N418, BioLegend, San Diego, CA, 
USA), anti-MHC-II APC/Cy7-congujated (clone M5/114.15.2, 
BioLegend, San Diego, CA, USA), or Zombie Aqua (BioLegend, 
San Diego, CA, USA) for 30 min and then fixed with a 2% para-
formaldehyde solution and then evaluated by flow cytometry. 
The percentage of FITC+ cells in CD11c+MHC-IIhighZAneg was 
determined.
Dc Migration to Popliteal lns
Bone marrow-derived DCs from WT or CAV1−/− mice were 
stained with carboxyfluorescein succinimidyl ester (CFSE, BD 
Biosciences, Franklin Lakes, NJ, USA) or CTV (BD Biosciences, 
Franklin Lakes, NJ, USA), respectively, according to protocols 
provided by the manufacturer. Then, labeled WT and CAV1−/− 
BM-DCs were mixed at a 1:1 ratio in PBS and 5 ×  105 total 
BM-DCs in 40 µl were injected into the footpad of the left lower 
extremity (footpad) of recipient WT mice. The exact percent-
age of WT and CAV1−/− actually injected (input DC) in was 
determined by FACS as CTV+ or CFSE+ cells in the mix and 
used to calculate “migration index.” After 24 h postinjection, 
draining popliteal lymph nodes of each limb were obtained 
and digested as described earlier. Single cell suspensions were 
labeled with anti-CD11c conjugated with APC/Cy7 (clone 
N418, BioLegend, San Diego, CA, USA) and anti-MHC-II 
conjugated with PerCP (clone M5/114.15.2, BioLegend, San 
Diego, CA, USA) and then analyzed by flow cytometry. The 
number of cells that migrated (migration index) was calculated 
as follows:
 
migration index stained DC in PLN   stained DC in inpu= % / % t








The mean of the values for control condition was defined as 1 
for further relativization.
Transwell assay
Transwell assays were performed in Boyden chambers (Transwell 
Costar, Thermo Scientific, Waltham, MA, USA, 6.5 mm diameter, 
8  µM pore). The outer side of the membrane was coated with 
2 µg/ml fibronectin for 18 h at 4°C. BM-DCs (2 × 104 in 200 µl of 
RPMI medium containing 0.5% FBS) were seeded in the upper 
chamber, and the same medium containing CCL21 (20  ng/ml, 
BioLegend, San Diego, CA, USA) was added to the lower cham-
ber to induce migration. After 1 h, the membranes were removed, 
washed, and stained with a solution containing 0.1% crystal violet 
in 2% ethanol and cells that migrated and adhered to the lower 
membrane surface were photographed under a microscope and 
counted. The migration index was calculated as follows:
 
migration index  number of migrated DC 
number of migrated
=
/  WT DC in control. 
The average of control condition was defined as 1 for further 
relativization.
Migration in Microchannels
Bone marrow-derived DCs were prepared for migration in 
microchannels as previously described (64), and the experiments 
were conducted as published before (64). In brief, the cells were 
introduced into the fibronectin (10  µg/ml)-coated microchan-
nels, without any mechanical or chemical stimulation. To assess 
the effect of LPS on DC migration in microchannels, BM-DCs 
were treated or not with LPS (1 µg/ml) for 30 min, followed by 
three rinses to wash out the LPS. After 5–6 h of LPS treatment, 
cells’ phase contrast images were recorded during 10–12  h at 
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various positions in the chambers and with 2  min time lapses 
(to record multiple fields at low resolution for statistics) using an 
automated microscope (Nikon ECLIPSE TE1000-E and Olympus 
X71, with a Marzhauser motorized stage and an HQ2 Roper 
camera) equipped with an environmental chamber to control 
temperature, humidity, and CO2 (Life Imaging Services). The 
analysis of migration parameters was performed as described 
previously (64).
Migration in collagen gels
Mature DCs were obtained by treating immature DCs with 
LPS (100  ng/ml) for 30  min and washing three times with 
supplemented medium. For collagen preparation, 120  µl of 
DCs (stock at 2 ×  106 million/ml) were carefully mixed with 
205  µl of bovine type I collagen (stock 6  mg/ml) (Advanced 
BioMatrix, San Diego, CA, USA) and 13 µl of NaHCO3 (stock 
7.5%) (Sigma-Aldrich, St. Louis, MO, USA). All solutions were 
previously equilibrated at 4°C. Then, the sample was loaded 
in a custom-made poly(dimethylsiloxane) (PDMS) “collagen 
chamber”. The chip was then incubated at 37°C for 30 min to 
allow collagen polymerization. To generate the CCL21 gradi-
ent, BM-DC medium containing 200  ng/ml of CCL21 (R&D 
Systems, Minneapolis, MN, USA) was added outside of the 
chamber. The cells were imaged by phase contrast at a frequency 
of 1 image every 2  min using a 10× objective. Images were 
processed to visualize cells by subtraction of the mean image 
of the whole movie at every time point, to obtain white objects 
on a dark background. Then cells were tracked as previously 
described (65).
confocal Microscopy and image 
acquisition
Bone marrow cells (2  ×  105) were cultured in 12-well plates 
containing 10  mm coverslips and differentiated into BM-DCs 
for 6 days using GM-CSF, as described. Cells were stimulated or 
not with LPS (100 ng/ml) for 24 h, washed three times with cold 
PBS and then fixed with 4% paraformaldehyde for 10 min at 4°C, 
washed again, permeabilized using Triton X-100 0.2% in PBS for 
10 min, and then blocked with a PBS-BSA 3% solution for 1 h 
at room temperature. The cells were incubated with anti-CAV1 
antibody (1: 200) overnight at 4°C, washed three times with PBS 
and then incubated 2  h at room temperature in the dark with 
anti-rabbit second antibody conjugated with Alexa Fluor 488 
(Thermo Scientific, Waltham, MA, USA) in a 1: 500 dilution 
together with 500 nM phalloidin rhodamine (Sigma-Aldrich, St. 
Louis, MO, USA) and 100  nM 4′,6-diamidino-2-phenylindole 
(Sigma-Aldrich, St. Louis, MO, USA). Coverslips were washed 
and mounted on microscope slides with Mowiol 4-88 (Sigma-
Aldrich, St. Louis, MO, USA), and samples were visualized with 
an Olympus IX81 DSU microscope and analyzed with ImageJ 
software. Membrane protrusions were counted manually for at 
least 10 cells per condition in two experiments.
rac1-gTP Pull-down assay
Rac1-GTP pull-down assays were performed as described previ-
ously (27). Briefly, cells were lysed in a buffer containing 25 mM 
HEPES (pH 7.4), 100 mM NaCl, 5 mM MgCl2, 1% NP-40, 10% 
glycerol, 1 mM dithiothreitol, and protease inhibitors. Extracts 
were incubated for 5 min on ice and clarified by centrifugation 
(10,000 × g, 1 min, 4°C). Supernatants were used for pull-down 
assays with 50 µg of GST-PAK1 pre-coated GSH beads per condi-
tion. Beads were incubated with supernatant for 15 min at 4°C in 
a rotating shaker. Thereafter, beads were collected, washed with 
lysis buffer containing 0.01% NP-40. Samples were separated 
by SDS-PAGE (12% acrylamide) and analyzed by Western 
blotting using anti-Rac1 (1:1,000) antibody from Transduction 
Laboratories (Lexington, KY, USA).
T cell Proliferation assay
Wild-type or CAV1−/− DCs were pulsed with different amounts 
of OVA257–264 peptide (10, 1, or 0.1  µg/ml) for 4  h and then 
washed. 5 × 103 DCs were cocultured with 1 × 105 CFSE-labeled 
(as described before) CD8+ T  cells purified from the spleen of 
OT-I mice using the EasySep CD8+ T Cell Enrichment Kit 
(StemCell, Vancouver, BC, Canada). Proliferation of CD8+ T cells 
was evaluated by assessing CFSE dilution by flow cytometry in 
the CD3+CD8+Vα2+ population using PerCP-conjugated anti-
CD3 (clone 145-1211, BioLegend, San Diego, CA, USA), 
APC-conjugated anti-CD8 (clone 53-6.7, BioLegend, San Diego, 
CA, USA), and Pacific Blue-conjugated anti-Vα2 (clone B20.1, 
BioLegend, San Diego, CA, USA).
Dc staining and cytokine secretion
Wild-type or CAV1−/− DCs were stimulated or not with LPS 
(100 ng/ml) for 24 h and then stained for 30 min at 4°C in 50 μl 
of PBS-BSA 2% solution with the following antibodies (all from 
BioLegend, San Diego, CA, USA): anti-CD11c APC-conjugated 
(clone N418, dilution 1:250), anti-CD40 PE-conjugated (clone 
3/23, dilution 1:125), anti-CD80 FITC-conjugated (clone 16- 
10A1, dilution 1:250), anti-CD86 PE/Cy7-conjugated (clone 
GL-1, dilution 1:250), anti-CD38 Alexa Fluor 488-conjugated 
(clone 90, dilution 1:200), anti-PD-L1 PE/Cy7-conjugated (clone 
10F.9G2, dilution 1:250), anti CD14 PE-conjugated (clone Sa14-
2, dilution 1:100), anti-CCR7 Brilliant Violet 421-conjugated 
(clone 4B12, dilution 1:100), anti-MHC-I PE-conjugated (clone 
M1/42, dilution 1:125), and anti-MHC-II PerCP-conjugated 
(clone M5/114.15.2, dilution 1:250). Zombie Aqua (BioLegend) 
was used to determine cell viability (1:500 dilution). Non-specific 
binding was blocked by mouse Fc receptor blocking (BioLegend, 
clone 93, dilution 1:100). Then, the cells were washed and fixed 
with 2% paraformaldehyde PBS and analyzed by flow cytometry. 
Approximately 10,000 events in the MHC-II+CD11+ gate were 
recorded per sample. Samples were acquired in a FACSCanto II 
cytometer (BD Bioscience), and the data analyzed using FlowJo 
version X (Tree Star Inc.). If correspond, the average of control 
condition was defined as 1 for further relativization. For the 
ELISA experiments, the supernatants of stimulated DCs were 
used to determine secretion of IL-6 (capture antibody: clone 
MP5-20F3; detection antibody: clone MP5-32C11); IL-12 (cap-
ture antibody: clone C18.2; detection antibody: clone C17.8), and 
TNF-α (capture antibody: clone MP6-XT22; detection antibody: 
C19.2), following the manufacturer’s instructions (BioLegend, 
San Diego, CA, USA).
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Dc immunization and evaluation  
of cD8+ T cell responses
Wild-type or CAV1−/− DCs pulsed with OVA257–264 peptide 
(10 µg/ml for 4 h) were washed three times with cold PBS and 
then injected intravenous (i.v., 106 cells) into recipient mice. 
PBS was used as vehicle control. Seven days after immunization, 
blood samples were obtained, and red blood cells were removed 
by using Red Blood Cells lysis buffer as described before. The 
samples were split in two fractions: one used for intracellular 
staining and the second for multimer staining. For intracellular 
cytokine staining, the cells were washed with PBS and stimulated 
ex vivo with OVA257–264 peptide (2.5  µg/ml) in supplemented 
RPMI. After 2 h, Golgi plug (brefeldin A) was added (1 µl/ml, BD 
Biosciences, Franklin Lakes, NJ, USA) for the last 6 h. Cells were 
first incubated with labeled with Fc receptor blocking (BioLegend, 
clone 93) and then labeled with the following antibodies (all from 
BioLegend, San Diego, CA, USA): PerCP-conjugated anti-CD3 
(clone 145-1211), APC/Cy7-conjugated anti-CD8 (clone 53-6.7), 
plus Zombie aqua (as viability dye). Then cells were fixed and 
permeabilized using BD Cytofix/Cytoperm Kit (BD Biosciences, 
Franklin Lakes, NJ, USA) according to the manufacturer’s instruc-
tions. Intracellular staining was performed using PE-conjugated 
anti-INF-γ (clone XMG1.2) and APC-conjugated anti-TNF-α 
(clone MP6-XT22) antibodies. For multimer staining, cells 
were incubated with Fc receptor blocking and labeled PerCP-
conjugated anti-CD3 (clone 145-1211), APC/Cy7-conjugated 
anti-CD8 (clone 53-6.7), Zombie aqua (as described earlier), 
and APC-conjugated MHC class I H-2Kb dextramer loaded with 
OVA257–264 peptide (SIINFEKL), according to the manufacturer’s 
instructions (Immudex, Copenhagen, Denmark).
Tumor challenge
After 12  days from DC immunization, mice were injected 
subcutaneously with B16F10-OVA tumor cells (2.5  ×  105 
cells in PBS, 95% >  viability, 60–80% confluence at harvesting 
day). The evaluation of tumor size (length, width, and height) 
started 5  days after challenge, and the volume was calculated 
as (length ×  width ×  height)/2. Mice were sacrificed if one of 
the measures exceeded 15 mm, to avoid unnecessary suffering. 
The tumor size was plotted against time post challenge, and the 
animal survival was plotted as Kaplan–Meier survival curve.
statistical analysis
Experimental data are presented as the mean ± SD or mean ± SEM 
of the number of experiments indicated as “n” or as representative 
results of at least two independent experiments. For determina-
tion of significance, data sets of two conditions were analyzed 
using Student’s t-test and Turkey’s post hoc analysis; for multiple 
data sets, one-way analysis of variance was used (ANOVA) and 
Bonferroni’s post hoc applied. Tumor growth was compared using 
the Wilcoxon rank sum test, and survival curves (Kaplan–Meier 
survival curve showing tumor-free survival) were compared 
using the Mantel–Cox test. A p value <0.05 was considered a 
statistically significant difference between the data compared 
(***p ≤ 0.001; **p ≤ 0.01, and *p ≤ 0.05).
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